Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 201 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 On legacy giving: “It allows me to give something more meaningful... October 13, 2021 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... February 19, 2021 Load more HOT NEWS My Path to Becoming a Radiation Therapist New Mom Was Told a Lump in Her Breast Was “Built-Up... CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate...
